FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2020439084> ?p ?o ?g. }

• W2020439084 endingPage "3380" @default.
• W2020439084 startingPage "3366" @default.
• W2020439084 abstract "Even when faced with elimination, functional materials may offer new alternatives to expensive drugs. Once used to treat benign prostate hypertrophy, the US Food and Drug Administration (FDA) suspended the use of lonidamine due to the occurrence of liver problems arising from its poor pharmaceutical properties. The objectives of the present study were to develop targeting lonidamine liposomes in combination with targeting epirubicin liposomes to circumvent drug-resistant cancer. Evaluations were performed on A549 and drug-resistant A549cDDP lung cancer cells and drug-resistant A549cDDP xenografted BALB/c nude mice. A DQA-PEG(2000)-DSPE conjugate was incorporated onto the liposomes as a targeting molecule. The constructed targeting lonidamine liposomes and targeting epirubicin liposomes measured were approximately 80 nm. The targeting lonidamine liposomes significantly enhanced the inhibitory effect of the targeting epirubicin liposomes in the drug-resistant A549cDDP cells in a lonidamine dose-dependent manner. Mechanism studies revealed that the targeting liposomes were selectively accumulated in the mitochondria, dissipating the mitochondrial membrane potential, opening the mitochondrial permeability transition pores, and releasing cytochrome C by translocation. This initiated a cascade of caspase 9 and 3 reactions and activated the pro-apoptotic Bax protein while suppressing the anti-apoptotic Mcl-1 protein, thereby enhancing the cytotoxic effect by acting on the mitochondrial signaling pathways. The efficacy in treating the drug-resistant A549cDDP xenografted tumor model after administration of the targeting lonidamine liposomes plus targeting epirubicin liposomes was the most significant compared with the administration of the controls at comparable doses. In conclusion, targeting lonidamine liposomes could be used as a potent co-therapy with an anticancer agent to enhance the efficacy of treating drug-resistant cancer by acting on the mitochondrial signaling pathways." @default.
• W2020439084 created "2016-06-24" @default.
• W2020439084 creator A5011182428 @default.
• W2020439084 creator A5012669971 @default.
• W2020439084 creator A5015105154 @default.
• W2020439084 creator A5018158708 @default.
• W2020439084 creator A5018359830 @default.
• W2020439084 creator A5037386960 @default.
• W2020439084 creator A5048063139 @default.
• W2020439084 creator A5062353528 @default.
• W2020439084 creator A5066599847 @default.
• W2020439084 creator A5069362421 @default.
• W2020439084 date "2013-04-01" @default.
• W2020439084 modified "2023-10-17" @default.
• W2020439084 title "Development of targeting lonidamine liposomes that circumvent drug-resistant cancer by acting on mitochondrial signaling pathways" @default.
• W2020439084 cites W1604468403 @default.
• W2020439084 cites W1964176183 @default.
• W2020439084 cites W1964483580 @default.
• W2020439084 cites W1968568156 @default.
• W2020439084 cites W1970485704 @default.
• W2020439084 cites W1976041621 @default.
• W2020439084 cites W1976779729 @default.
• W2020439084 cites W1977116179 @default.
• W2020439084 cites W1978249092 @default.
• W2020439084 cites W1981989535 @default.
• W2020439084 cites W1985241728 @default.
• W2020439084 cites W1987885263 @default.
• W2020439084 cites W1993672158 @default.
• W2020439084 cites W1995200008 @default.
• W2020439084 cites W2019250045 @default.
• W2020439084 cites W2027542963 @default.
• W2020439084 cites W2030101690 @default.
• W2020439084 cites W2030680926 @default.
• W2020439084 cites W2034224323 @default.
• W2020439084 cites W2043315157 @default.
• W2020439084 cites W2046104345 @default.
• W2020439084 cites W2048746306 @default.
• W2020439084 cites W2057472478 @default.
• W2020439084 cites W2074001680 @default.
• W2020439084 cites W2076784218 @default.
• W2020439084 cites W2081914868 @default.
• W2020439084 cites W2083803551 @default.
• W2020439084 cites W2089663038 @default.
• W2020439084 cites W2091400260 @default.
• W2020439084 cites W2106877996 @default.
• W2020439084 cites W2144277227 @default.
• W2020439084 cites W2325702139 @default.
• W2020439084 cites W2626223149 @default.
• W2020439084 doi "https://doi.org/10.1016/j.biomaterials.2013.01.055" @default.
• W2020439084 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23410681" @default.
• W2020439084 hasPublicationYear "2013" @default.
• W2020439084 type Work @default.
• W2020439084 sameAs 2020439084 @default.
• W2020439084 citedByCount "86" @default.
• W2020439084 countsByYear W20204390842014 @default.
• W2020439084 countsByYear W20204390842015 @default.
• W2020439084 countsByYear W20204390842016 @default.
• W2020439084 countsByYear W20204390842017 @default.
• W2020439084 countsByYear W20204390842018 @default.
• W2020439084 countsByYear W20204390842019 @default.
• W2020439084 countsByYear W20204390842020 @default.
• W2020439084 countsByYear W20204390842021 @default.
• W2020439084 countsByYear W20204390842022 @default.
• W2020439084 countsByYear W20204390842023 @default.
• W2020439084 crossrefType "journal-article" @default.
• W2020439084 hasAuthorship W2020439084A5011182428 @default.
• W2020439084 hasAuthorship W2020439084A5012669971 @default.
• W2020439084 hasAuthorship W2020439084A5015105154 @default.
• W2020439084 hasAuthorship W2020439084A5018158708 @default.
• W2020439084 hasAuthorship W2020439084A5018359830 @default.
• W2020439084 hasAuthorship W2020439084A5037386960 @default.
• W2020439084 hasAuthorship W2020439084A5048063139 @default.
• W2020439084 hasAuthorship W2020439084A5062353528 @default.
• W2020439084 hasAuthorship W2020439084A5066599847 @default.
• W2020439084 hasAuthorship W2020439084A5069362421 @default.
• W2020439084 hasConcept C121608353 @default.
• W2020439084 hasConcept C126322002 @default.
• W2020439084 hasConcept C178790620 @default.
• W2020439084 hasConcept C185154212 @default.
• W2020439084 hasConcept C185592680 @default.
• W2020439084 hasConcept C190283241 @default.
• W2020439084 hasConcept C2779820397 @default.
• W2020439084 hasConcept C2780035454 @default.
• W2020439084 hasConcept C2780835546 @default.
• W2020439084 hasConcept C530470458 @default.
• W2020439084 hasConcept C55493867 @default.
• W2020439084 hasConcept C71924100 @default.
• W2020439084 hasConcept C98274493 @default.
• W2020439084 hasConceptScore W2020439084C121608353 @default.
• W2020439084 hasConceptScore W2020439084C126322002 @default.
• W2020439084 hasConceptScore W2020439084C178790620 @default.
• W2020439084 hasConceptScore W2020439084C185154212 @default.
• W2020439084 hasConceptScore W2020439084C185592680 @default.
• W2020439084 hasConceptScore W2020439084C190283241 @default.
• W2020439084 hasConceptScore W2020439084C2779820397 @default.
• W2020439084 hasConceptScore W2020439084C2780035454 @default.
• W2020439084 hasConceptScore W2020439084C2780835546 @default.
• W2020439084 hasConceptScore W2020439084C530470458 @default.

• next